Callan Family Office LLC purchased a new position in Fresenius Medical Care AG (NYSE:FMS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 22,183 shares of the company's stock, valued at approximately $502,000.
A number of other hedge funds have also made changes to their positions in the stock. Venturi Wealth Management LLC grew its stake in Fresenius Medical Care by 8.4% in the fourth quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company's stock valued at $129,000 after purchasing an additional 441 shares in the last quarter. MML Investors Services LLC lifted its stake in Fresenius Medical Care by 5.3% in the third quarter. MML Investors Services LLC now owns 15,019 shares of the company's stock valued at $320,000 after acquiring an additional 753 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Fresenius Medical Care by 192.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company's stock worth $28,000 after purchasing an additional 806 shares during the last quarter. DAVENPORT & Co LLC raised its holdings in shares of Fresenius Medical Care by 1.5% during the 4th quarter. DAVENPORT & Co LLC now owns 58,147 shares of the company's stock valued at $1,316,000 after purchasing an additional 862 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in Fresenius Medical Care by 5.8% during the fourth quarter. Bank of New York Mellon Corp now owns 21,951 shares of the company's stock worth $497,000 after buying an additional 1,205 shares during the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on FMS. Truist Financial raised their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the company a "hold" rating in a research note on Monday, January 6th. StockNews.com upgraded shares of Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Finally, Bank of America upgraded Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research note on Monday, December 2nd.
Get Our Latest Report on FMS
Fresenius Medical Care Stock Performance
Shares of NYSE:FMS traded down $1.08 on Thursday, hitting $23.12. 362,837 shares of the company were exchanged, compared to its average volume of 279,503. Fresenius Medical Care AG has a one year low of $17.93 and a one year high of $25.25. The firm has a market capitalization of $13.56 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 0.76 and a beta of 0.99. The company's 50 day moving average price is $23.61 and its two-hundred day moving average price is $22.13. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.
About Fresenius Medical Care
(
Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
See Also
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
